Sanctuary Advisors LLC Acquires 464 Shares of Insmed Incorporated (NASDAQ:INSM)

Sanctuary Advisors LLC lifted its holdings in shares of Insmed Incorporated (NASDAQ:INSM) by 13.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,861 shares of the biopharmaceutical company’s stock after purchasing an additional 464 shares during the period. Sanctuary Advisors LLC’s holdings in Insmed were worth $295,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Nisa Investment Advisors LLC grew its holdings in Insmed by 88.4% during the 3rd quarter. Nisa Investment Advisors LLC now owns 3,350 shares of the biopharmaceutical company’s stock valued at $245,000 after buying an additional 1,572 shares in the last quarter. US Bancorp DE boosted its stake in Insmed by 55.3% in the third quarter. US Bancorp DE now owns 7,932 shares of the biopharmaceutical company’s stock worth $579,000 after buying an additional 2,824 shares in the last quarter. Harbor Capital Advisors Inc. purchased a new stake in Insmed in the third quarter worth approximately $1,291,000. Van ECK Associates Corp purchased a new stake in Insmed in the third quarter worth approximately $9,138,000. Finally, AlphaCentric Advisors LLC bought a new stake in Insmed in the third quarter valued at approximately $365,000.

Insider Activity

In other news, CEO William Lewis sold 18,750 shares of Insmed stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $81.03, for a total value of $1,519,312.50. Following the completion of the sale, the chief executive officer now directly owns 334,186 shares of the company’s stock, valued at approximately $27,079,091.58. The trade was a 5.31 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Sara Bonstein sold 1,066 shares of the business’s stock in a transaction on Friday, January 10th. The stock was sold at an average price of $63.72, for a total value of $67,925.52. Following the transaction, the chief financial officer now directly owns 118,863 shares of the company’s stock, valued at $7,573,950.36. The trade was a 0.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 532,207 shares of company stock worth $41,400,465 over the last quarter. 4.60% of the stock is currently owned by corporate insiders.

Insmed Stock Up 1.2 %

Insmed stock opened at $77.21 on Wednesday. The firm has a market cap of $13.97 billion, a price-to-earnings ratio of -13.81 and a beta of 1.11. Insmed Incorporated has a 52 week low of $21.92 and a 52 week high of $84.91. The business’s 50-day moving average price is $75.32 and its 200 day moving average price is $73.81. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03.

Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.15). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The business had revenue of $104.44 million during the quarter, compared to analyst estimates of $102.31 million. As a group, sell-side analysts anticipate that Insmed Incorporated will post -4.56 earnings per share for the current year.

Wall Street Analyst Weigh In

INSM has been the subject of a number of recent analyst reports. Truist Financial upped their target price on Insmed from $105.00 to $108.00 and gave the company a “buy” rating in a report on Friday, February 21st. Stifel Nicolaus decreased their price objective on Insmed from $97.00 to $96.00 and set a “buy” rating for the company in a report on Friday, February 21st. Cantor Fitzgerald reissued an “overweight” rating on shares of Insmed in a research note on Wednesday, February 19th. Morgan Stanley increased their price objective on Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a research report on Thursday, February 6th. Finally, Royal Bank of Canada initiated coverage on Insmed in a research report on Tuesday, February 25th. They set an “outperform” rating and a $100.00 price objective on the stock. One research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $91.60.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.